NAION and Tirzepatide: Separating the Evidence from the Headlines

The misconception worth correcting first: NAION is not a confirmed side effect of tirzepatide

When a study published in mid-2024 reported higher rates of NAION among semaglutide users compared with non-GLP-1 controls, the finding spread quickly — and in many retellings tirzepatide and mounjaro naion were bundled into the same story, as though the evidence applied equally to both medicines. It does not, at least not yet. The 2024 retrospective study focused on semaglutide, not tirzepatide, and observational studies of this kind identify associations rather than causes. Association is not causation, particularly when the population using these medicines tends to have conditions (obesity, type 2 diabetes, hypertension) that are themselves independent risk factors for vascular events affecting the eye.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. You can read more about how it works on our tirzepatide overview page. Its pharmacology differs from semaglutide in ways that may or may not be clinically relevant to optic nerve blood flow, that question remains under active study.

The honest position, and the one that regulators currently hold, is that the signal is unresolved: it is being watched carefully, but it has not translated into a confirmed causal relationship with tirzepatide specifically.

What NAION is and why the optic nerve is vulnerable

Non-arteritic anterior ischaemic optic neuropathy is caused by a sudden interruption to blood supply at the anterior portion of the optic nerve. The result is painless, often permanent vision loss in the affected eye, typically noticed on waking. It is rare (estimated UK incidence is around two to ten cases per 100,000 people annually) but it is the most common acute optic neuropathy in adults over 50. People with a structurally small optic disc (sometimes called a "disc at risk"), poorly controlled blood pressure, sleep apnoea, or a history of cardiovascular disease carry higher baseline risk. These conditions overlap considerably with the population for whom tirzepatide is prescribed, which is precisely why unpicking a drug signal from background risk is difficult in observational data.

GLP-1 medicines affect vascular tone, intraocular pressure, and blood pressure, all physiologically plausible pathways if a link were to be confirmed. Researchers are exploring them. That work is ongoing and worth watching; it does not yet support a clinical conclusion that tirzepatide and NAION are causally connected. The NHS tirzepatide medicines page lists the currently recognised side effects of Mounjaro, and sudden vision change is included in its warnings for urgent medical review, consistent with general vascular vigilance rather than a confirmed NAION-specific signal.

What regulators are doing and what you should do

The MHRA runs a continuous pharmacovigilance programme for all licensed medicines, and tirzepatide carries a Black Triangle (▼) designation, meaning it receives additional monitoring precisely because it is relatively new. If you experience a suspected side effect (including any sudden vision change) you can report it directly at the MHRA's Yellow Card scheme. Those reports feed into the signal-detection process and genuinely influence regulatory decisions.

For patients currently taking tirzepatide, the practical guidance is straightforward: sudden, painless vision loss or blurring in one eye is a medical emergency regardless of its cause. Do not attribute it to tiredness or screen time and wait it out. Go to A&E or call 111 the same day. Early intervention can sometimes limit permanent damage in vascular optic events.

For people considering treatment, tirzepatide's overall safety profile across the SURMOUNT clinical programme (which enrolled thousands of adults) remains the basis on which NICE recommended it in December 2024. That assessment factored in the reported side-effect data available at the time. If you have pre-existing eye conditions, high blood pressure, sleep apnoea, or cardiovascular history, those are exactly the things a prescriber needs to know about during your consultation. Our clinical team profiles are on the prescriber page if you want to understand who reviews consultations at nume.

Questions worth raising at your consultation

This is a genuinely evolving area of pharmacovigilance, and a good consultation should have space for it. Some questions worth thinking about before yours: Do you have a history of NAION in one eye, which increases risk in the other? Do you have a small optic disc (sometimes identified during routine eye tests)? Is your blood pressure well controlled? Are you under active follow-up with an ophthalmologist for any other reason?

A prescriber cannot eliminate uncertainty about a signal that science itself has not resolved, but they can weigh your individual risk profile and decide whether the balance of likely benefit versus potential risk is appropriate for you. That is the job clinical assessment is designed to do. If you would like to explore weight-loss treatment options in that context, the information is there; a conversation with a prescriber is the right next step.

For those comparing options and wondering how this fits into the broader picture of tirzepatide versus semaglutide, the Mounjaro or tirzepatide page covers the evidence on both medicines side by side. If you are researching specific doses, you can find detailed information on tirzepatide 10, guidance on tirzepatide 30, and an overview of tirzepatide l on their respective pages. And if cost is part of your thinking, the Mounjaro cost page addresses that honestly. At nume, one transparent price covers consultation, prescription, and free next-working-day delivery, no subscriptions, no hidden fees. Speak to our prescribers about whether treatment is right for you.